- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 211/34
Total number of patents in this class: 434
10-year publication summary
26
|
31
|
21
|
27
|
33
|
29
|
31
|
38
|
19
|
13
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Incyte Corporation | 1018 |
15 |
Incyte Holdings Corporation | 651 |
13 |
Zevra Therapeutics, Inc. | 99 |
13 |
Novartis AG | 10886 |
11 |
Biogen MA Inc. | 893 |
11 |
Boehringer Ingelheim International GmbH | 4697 |
8 |
AstraZeneca AB | 2928 |
7 |
Massachusetts Institute of Technology | 10030 |
7 |
Takeda Pharmaceutical Company Limited | 2712 |
7 |
Nocion Therapeutics, Inc. | 42 |
7 |
ReNAgade Therapeutics Management Inc. | 44 |
7 |
The General Hospital Corporation | 4715 |
6 |
The Broad Institute, Inc. | 1793 |
6 |
Guangzhou Innocare Pharma Tech Co., Ltd. | 12 |
6 |
Praxis Precision Medicines, Inc. | 175 |
6 |
ChemoCentryx, Inc. | 387 |
5 |
AstraZeneca UK Limited | 655 |
4 |
Janssen Pharmaceutica N.V. | 3396 |
4 |
Merck Sharp & Dohme Limited | 51 |
4 |
The Regents of the University of Michigan | 4676 |
4 |
Other owners | 283 |